AstraZeneca Gets EU Approval for Ultomiris Drug
23 September 2022 - 8:42AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Friday that its Ultomiris drug has been
approved in the European Union for the treatment of adults with the
rare disease generalized myasthenia gravis.
The Anglo-Swedish pharma giant said that Ultomiris may reduce
treatment burden with dosing every eight weeks, it said, adding
that the drug also proved an improvement in activities of daily
living.
Generalized myasthenia gravis is a rare autoimmune neuromuscular
disease that leads to a loss of muscle function and severe
weakness, AstraZeneca said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 23, 2022 02:27 ET (06:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
